Want to see BNBX full AI Analyst Report?
BNBX Stock Chart & Stats
$0.09
<$0.01(5.92%)
At close: 4:00 PM EDT
$0.09
<$0.01(5.92%)
Day’s Range― - ―
52-Week Range$0.07 - $7.15
Previous CloseN/A
Volume2.78K
Average Volume (3M)1.96M
Market Cap
$863.89K
Enterprise Value$2.64
Total Cash (Recent Filing)$949.09K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,197,223
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces mandatory financing costs and balance-sheet risk, giving BNB Plus more flexibility to fund operations or restructure. However, this benefit is limited because ongoing losses and cash consumption may still require external capital.
Revenue ReboundThe sharp TTM revenue rebound indicates that the company retains some ability to generate demand and expand its operating base. If sustained and paired with cost control, this growth could improve fixed-cost absorption and support future profitability.
Financing And Strategic OptionsThe preferred-stock financing provides capital to support the strategic review and ongoing operations, while the company is evaluating monetization of its profitable LineaRx DNA unit. These steps may extend runway and create alternatives for funding recovery.
Bears Say
Extreme UnprofitabilityThe revenue rebound has not translated into earnings power: very low gross margin and an outsized cost base continue to produce extreme operating and net losses. Sustained losses weaken value creation and make a durable turnaround dependent on major restructuring.
Heavy Cash BurnDeeply negative operating and free cash flow show that the business is consuming substantial capital rather than funding itself. Continued burn increases reliance on financings, which can dilute existing holders and constrain strategic choices if operating performance does not improve.
Listing And Governance DisruptionThe move from Nasdaq to OTCQB is expected to reduce liquidity, while senior leadership departures and terminated advisory agreements increase execution and governance uncertainty. Together, these changes can make capital access, investor support, and strategic implementation more difficult.
BNB Plus News
BNBX FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was $0.07 and its highest was $7.15 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is $863.89K.
When is BNB Plus’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BNB Plus’s earnings last quarter?
Currently, no data Available
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 6,197,223 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in BNBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―
Ownership Overview
2.72% Insiders
0.48% Mutual Funds
4.99% Other Institutional Investors
91.80% Public Companies and
Individual Investors